XGN – Exagen Inc.
XGN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.44
Margin Of Safety %
Put/Call OI Ratio
0.02
EPS Next Q Diff
EPS Last/This Y
0.13
EPS This/Next Y
0.49
Price
2.68
Target Price
9.5
Analyst Recom
1
Performance Q
-56.7
Upside
-1,301.5%
Beta
1.96
Ticker: XGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | XGN | 3.6 | 0.07 | 0.08 | 835 |
| 2026-03-02 | XGN | 3.54 | 0.07 | 0.08 | 835 |
| 2026-03-03 | XGN | 3.43 | 0.07 | 0.08 | 835 |
| 2026-03-04 | XGN | 3.6 | 0.07 | 0.08 | 835 |
| 2026-03-05 | XGN | 3.22 | 0.07 | 0.08 | 835 |
| 2026-03-06 | XGN | 3.29 | 0.07 | 0.00 | 852 |
| 2026-03-09 | XGN | 3.37 | 0.07 | 0.00 | 852 |
| 2026-03-10 | XGN | 3.24 | 0.07 | 0.00 | 853 |
| 2026-03-11 | XGN | 3.11 | 0.07 | 0.00 | 863 |
| 2026-03-12 | XGN | 3.16 | 0.07 | 0.00 | 893 |
| 2026-03-13 | XGN | 3.16 | 0.07 | 0.00 | 893 |
| 2026-03-17 | XGN | 3.18 | 0.06 | 10.00 | 913 |
| 2026-03-18 | XGN | 3 | 0.13 | 999.99 | 974 |
| 2026-03-19 | XGN | 2.96 | 0.13 | 999.99 | 974 |
| 2026-03-20 | XGN | 2.8 | 0.23 | 0.00 | 1055 |
| 2026-03-23 | XGN | 2.84 | 0.23 | 0.00 | 1055 |
| 2026-03-24 | XGN | 2.75 | 0.23 | 0.00 | 1055 |
| 2026-03-25 | XGN | 2.88 | 0.23 | 0.00 | 1055 |
| 2026-03-26 | XGN | 2.8 | 0.02 | 0.00 | 862 |
| 2026-03-27 | XGN | 2.68 | 0.02 | 0.00 | 862 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | XGN | 3.58 | 3.3 | 13.8 | -0.84 |
| 2026-03-02 | XGN | 3.55 | 3.3 | 5.6 | -0.84 |
| 2026-03-03 | XGN | 3.43 | 3.3 | 5.7 | -0.84 |
| 2026-03-04 | XGN | 3.60 | 3.3 | 4.9 | -0.84 |
| 2026-03-05 | XGN | 3.21 | 3.3 | 6.6 | -0.84 |
| 2026-03-06 | XGN | 3.29 | 3.3 | 5.1 | -0.84 |
| 2026-03-09 | XGN | 3.38 | 3.3 | 4.9 | -0.84 |
| 2026-03-10 | XGN | 3.20 | 3.3 | 5.9 | -0.84 |
| 2026-03-11 | XGN | 3.11 | 3.3 | 5.9 | -0.84 |
| 2026-03-12 | XGN | 3.16 | 3.3 | 5.1 | -0.84 |
| 2026-03-13 | XGN | 3.05 | -25.0 | 4.1 | -0.80 |
| 2026-03-17 | XGN | 3.19 | -25.0 | 3.5 | -0.80 |
| 2026-03-18 | XGN | 3.01 | -25.0 | 14.1 | -0.80 |
| 2026-03-19 | XGN | 2.96 | -25.0 | 3.9 | -0.80 |
| 2026-03-20 | XGN | 2.79 | -25.0 | 4.5 | -0.80 |
| 2026-03-23 | XGN | 2.86 | -25.0 | 3.6 | -0.80 |
| 2026-03-24 | XGN | 2.74 | -25.0 | 4.2 | -0.80 |
| 2026-03-25 | XGN | 2.88 | -25.0 | 3.2 | -0.80 |
| 2026-03-26 | XGN | 2.78 | -25.0 | 4.2 | -0.80 |
| 2026-03-27 | XGN | 2.68 | -25.0 | 4.2 | -0.80 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | XGN | -0.79 | 15.66 | 6.12 |
| 2026-03-02 | XGN | -0.79 | 11.08 | 6.12 |
| 2026-03-03 | XGN | -0.79 | 11.08 | 6.12 |
| 2026-03-04 | XGN | -0.98 | 11.08 | 6.12 |
| 2026-03-05 | XGN | -0.73 | 11.08 | 6.12 |
| 2026-03-06 | XGN | -0.73 | 11.08 | 6.12 |
| 2026-03-09 | XGN | -0.73 | 10.99 | 6.12 |
| 2026-03-10 | XGN | -0.73 | 10.99 | 6.12 |
| 2026-03-11 | XGN | -0.73 | 10.99 | 7.40 |
| 2026-03-12 | XGN | -0.73 | 10.99 | 7.40 |
| 2026-03-13 | XGN | -0.69 | 10.99 | 6.97 |
| 2026-03-17 | XGN | -0.69 | 10.62 | 6.97 |
| 2026-03-18 | XGN | -0.69 | 10.62 | 6.97 |
| 2026-03-19 | XGN | -0.69 | 10.62 | 6.97 |
| 2026-03-20 | XGN | -0.69 | 10.62 | 6.97 |
| 2026-03-23 | XGN | -0.69 | 10.63 | 6.97 |
| 2026-03-24 | XGN | -0.69 | 10.63 | 6.97 |
| 2026-03-25 | XGN | -0.69 | 10.63 | 7.44 |
| 2026-03-26 | XGN | -0.69 | 10.63 | 7.44 |
| 2026-03-27 | XGN | -0.69 | 10.63 | 7.44 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.2
Avg. EPS Est. Current Quarter
-0.25
Avg. EPS Est. Next Quarter
-0.2
Insider Transactions
-0.69
Institutional Transactions
10.63
Beta
1.96
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
17
Fair Value
Quality Score
36
Growth Score
45
Sentiment Score
2
Actual DrawDown %
85.5
Max Drawdown 5-Year %
-92.4
Target Price
9.5
P/E
Forward P/E
PEG
P/S
0.97
P/B
3.52
P/Free Cash Flow
EPS
-0.92
Average EPS Est. Cur. Y
-0.8
EPS Next Y. (Est.)
-0.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-29.97
Relative Volume
0.56
Return on Equity vs Sector %
-141.7
Return on Equity vs Industry %
-125.4
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.34
EBIT Estimation
4.2
◆
XGN
Healthcare
$2.68
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
31.7
Range 1M
3.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
25.8%
EPS NY
36.9%
52W%
0.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+254.5% upside
Upside
+254.5%
Quality
36
Exagen Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 216
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
XGN
Latest News
—
Caricamento notizie per XGN…
stock quote shares XGN – Exagen Inc. Stock Price stock today
news today XGN – Exagen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch XGN – Exagen Inc. yahoo finance google finance
stock history XGN – Exagen Inc. invest stock market
stock prices XGN premarket after hours
ticker XGN fair value insiders trading